source
- Revolution Medicines eyes broader use of daraxonrasib pending FDA submissionRevolution Medicines' daraxonrasib has not yet been approved for metastatic pancreatic cancer after chemotherapy, but a recent ASCO plenary presentation generated strong interest. Analysts expect…
- Lawmakers backtrack on promised Medicaid protections for cancer patients, new CMS rules impose work requirementsGwen Nichols, a hematologist/oncologist and chief medical officer of Blood Cancer United, wrote that lawmakers who pledged to protect cancer patients from Medicaid cuts are now backing a policy tha…